Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Head and Neck

Document Type : Original Article (s)

Authors

1 Professor, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cyclooxygenases-2(COX) expression in cancer tissues is associated with worse prognosis of cancers. We studied cyclooxigenase-2 expression among patients with head and neck squamous cell carcinoma (HNSCC).Methods: In a cross-sectional study performed in two university hospitals in Isfahan City, Iran, between the years 2011 and 2015, patients with newly pathological diagnosis of HNSCC were evaluated. Real-time polymerase chain reaction (real-time PCR) was used to evaluate the expression of cyclooxigenase-2 in surgical excised cancer tissues. Patients were followed-up for one year regarding recurrence and mortality. Association of cyclooxigenase-2 expression with clinicopathologic data and prognosis were analyzed.Findings: Thirty cases of HNSCC with mean age of 59.6 years (70% men) were studied. Only 4 cases (13.3%) were cyclooxigenase-2 positive. Compared with cyclooxigenase-2 negative cases, those with cyclooxigenase-2 expression were relatively, but not significantly, older (71.0 ± 12.5 vs. 57.8±12.0 years, P = 0.054) and had larger tumor size (2.70 ± 1.19 vs. 1.76 ± 0.84 cm, P = 0.061), more frequent moderately/poorly differentiated tumors (50.0 vs. 15.3 percent, P = 0.190), and more frequent involvement of the lymph nodes (50.0 vs. 7.6 percent, P = 0.075). One of the cyclooxigenase-2 positive cases had metastasis. After one year follow-up, recurrence rate was 75.0% and 9.5% in cyclooxigenase-2 positive and negative cases, respectively (P = 0.005).Conclusion: We found that cyclooxigenase-2 expression in HNSCC patients is associated with worse clinicopathologic characteristics and prognosis. It may be used as a prognostic factor for HNSCC and also a target for treatment. Further studies with larger sample size are warranted in this regard.

Keywords

References

  1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11(1): 9-22.
  2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45(4-5): 309-16.
  3. van Houten VM, van den Brekel MW, Denkers F, Colnot DR, Westerga J, van Diest PJ, et al. Molecular diagnosis of head and neck cancer. Recent Results Cancer Res 2000; 157: 90-106.
  4. Bennett A, Carter RL, Stamford IF, Tanner NS. Prostaglandin-like material extracted from squamous carcinomas of the head and neck. Br J Cancer 1980; 41(2): 204-8.
  5. Bennett A, Carroll MA, Stamford IF, Whimster WF, Williams F. Prostaglandins and human lung carcinomas. Br J Cancer 1982; 46(6): 888-93.
  6. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86(6): 347-63.
  7. Chou J, Lin YC, Kim J, You L, Xu Z, He B, et al. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck 2008; 30(7): 946-63.
  8. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5): 705-16.
  9. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56(22): 5125-7.
  10. Schrey MP, Patel KV. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 1995; 72(6): 1412-9.
  11. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3(1): 53-61.
  12. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276(24): 20809-12.
  13. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58(17): 3761-4.
  14. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90(6): 455-60.
  15. Qiu ZQ, Qiu ZR. Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression. Asian Pac J Cancer Prev 2015; 16(8): 3447-50.
  16. Shimizu K, Yukawa T, Okita R, Saisho S, Maeda A, Nojima Y, et al. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol 2015; 13: 21.
  17. Peng JP, Su CY, Chang HC, Chai CY, Hung WC.
  18. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002; 33(1): 100-4.
  19. Sudbo J, Ristimaki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003; 39(5): 497-505.
  20. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002; 33(7): 708-14.
  21. Yang Y, Yan J, Huang Y, Xu H, Zhang Y, Hu R, et al. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. Biomed Pharmacother 2015; 70: 181-9.
  22. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24(8): 792-9.
  23. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268(12): 9049-54.
  24. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14(7): 1021-31.
  25. Kojima M, Morisaki T, Uchiyama A, Doi F, Mibu R, Katano M, et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 2001; 8(5): 458-65.
  26. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010; 62(2): 233-44.
  27. Gillespie MB, Moody MW, Lee FS, Poole LJ, Hornig JD, Lathers D, et al. Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users. Arch Otolaryngol Head Neck Surg 2007; 133(1): 28-31.
  28. Nystrom ML, McCulloch D, Weinreb PH, Violette SM, Speight PM, Marshall JF, et al. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 2006; 66(22): 10833-42.
  29. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: Preclinical and clinical studies. Clin Cancer Res 2013; 19(5): 1244-56.
Journal of Isfahan Medical School
Volume 35, Issue 443 - Serial Number 443
July and August 2017
Pages 1038-1043

Files

History

  • Receive Date: 10 October 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics